Abstract
Imatinib is used as first-line treatment for chronic myeloid leukemia
(CML) even in patients with impaired renal function. We successfully
used therapeutic drug monitoring to determine the dose for
re-administration of imatinib in a CML patient who initiated dialysis
for acute renal dysfunction associated with the initial imatinib
therapy.